PLK1 and breast carcinoma: (2012) examined the cytotoxic response of several Plk1 inhibitors, including volasertib, BI2536, and poloxin, in a series of isogenic cell lines differing in p53 status derived from breast cancer, lung cancer, colon cancer, and cervical carcinoma.